Condition: NSCLC Stage IV · NSCLC, Stage III · Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
ROS1 rearrangements are rare, accounting for only 1-2% of NSCLC cases, but have been associated with response to ROS1 inhibitors, such as crizotinib and entrectinib. However, many patients develop resistance to the tyrosine-kinase inhibitors (TKIs), creating a need for new treatments. Repotrectinib is a new-generation TKI designed against ROS1 or NTRK rearranged malignancies (Drilon 2018). Early phase clinical data support activity of repotrectinib in patients with NSCLC harboring such gene rearrangements (TRIDENT-1 study), but there are limited evidence in frail populations, such as poor performance status patients and/or elderly patients, who are classically excluded from clinical trials or underrepresented. The present study aims to assess the activity and tolerability of repotrectinib in frail (PS ≥2) and/or elderly patients with ROS1-rearranged advanced NSCLC.
This description comes directly from the study's public registry record.
Sophie Lafond · 0483772062 · sophie.lafond@ch-toulon.fr
Soizic Ferlandin · 0663224789 · soizic_ferlandin@yahoo.fr
Always discuss trial participation with your own doctor first.
| CH Aix-en-Provence | Aix-en-Provence, Bouches Du Rhône, France | Recruiting |
| AP-HM | Marseille, Bouches Du Rhône, France | Recruiting |
| HIA Sainte Anne | Toulon, Var, France | Recruiting |
| CHU Angers | Angers, France | Recruiting |
| CHU Bordeaux | Bordeaux, France | Recruiting |
| CHU Brest | Brest, France | Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| CH Chambéry | Chambéry, France | Recruiting |
| Hôpitaux civils de Colmar | Colmar, France | Recruiting |
| CHI Créteil | Créteil, France | Recruiting |
| CHD Vendée | La Roche-sur-Yon, France | Recruiting |
| CHRU Lille | Lille, France | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06552234